Moderna (MRNA) beats estimates in Q1 2024, targets RSV vaccine launch in fall
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains over 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Moderna (MRNA) PT Raised to $135 at RBC Capital
May 3, 2024 6:45 AM EDTRBC Capital analyst Luca Issi raised the price target on Moderna (NASDAQ: MRNA) to $135.00 (from $125.00) while maintaining a Outperform rating.
The analyst comments "Bottom line was a beat primarily on lower OpEx. Guide was reiterated ($4b revenue and $8.1b costs), and we like... More
Moderna (MRNA) PT Raised to $95 at Morgan Stanley
May 2, 2024 4:14 PM EDTMorgan Stanley analyst Matthew Harrison raised the price target on Moderna (NASDAQ: MRNA) to $95.00 (from $89.00) while maintaining a Equalweight rating.
The analyst comments "Generally in line quarter, looking ahead the next catalysts for the stock are RSV vaccine PDUFA date May 12 (followed... More
Moderna (MRNA) Tops Q1 EPS by 48c
May 2, 2024 6:35 AM EDTModerna (NASDAQ: MRNA) reported Q1 EPS of ($3.07), $0.48 better than the analyst estimate of ($3.55). Revenue for the quarter came in at $167 billion versus the consensus estimate of $94.28 million.
For earnings history and earnings-related data on Moderna (MRNA) click here.
... More